Aytu BioPharma (AYTU) Competitors $1.89 -0.17 (-8.30%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AYTU vs. CNTB, ASRT, EQ, CNTX, OVID, QNCX, SLGL, KLRS, ATRA, and ALTSShould you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Connect Biopharma (CNTB), Assertio (ASRT), Equillium (EQ), Context Therapeutics (CNTX), Ovid Therapeutics (OVID), Quince Therapeutics (QNCX), Sol-Gel Technologies (SLGL), Kalaris Therapeutics (KLRS), Atara Biotherapeutics (ATRA), and ALT5 Sigma (ALTS). These companies are all part of the "pharmaceutical products" industry. Aytu BioPharma vs. Its Competitors Connect Biopharma Assertio Equillium Context Therapeutics Ovid Therapeutics Quince Therapeutics Sol-Gel Technologies Kalaris Therapeutics Atara Biotherapeutics ALT5 Sigma Connect Biopharma (NASDAQ:CNTB) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Do insiders and institutionals hold more shares of CNTB or AYTU? 58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 3.6% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor CNTB or AYTU? In the previous week, Aytu BioPharma had 11 more articles in the media than Connect Biopharma. MarketBeat recorded 12 mentions for Aytu BioPharma and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 0.00 beat Aytu BioPharma's score of -0.29 indicating that Connect Biopharma is being referred to more favorably in the media. Company Overall Sentiment Connect Biopharma Neutral Aytu BioPharma Neutral Do analysts prefer CNTB or AYTU? Connect Biopharma presently has a consensus price target of $7.00, suggesting a potential upside of 298.86%. Aytu BioPharma has a consensus price target of $10.25, suggesting a potential upside of 442.62%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Connect Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, CNTB or AYTU? Connect Biopharma has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Which has preferable earnings and valuation, CNTB or AYTU? Connect Biopharma has higher earnings, but lower revenue than Aytu BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioConnect Biopharma$1.97M49.77-$15.63MN/AN/AAytu BioPharma$81.66M0.21-$15.84M-$2.82-0.67 Is CNTB or AYTU more profitable? Connect Biopharma has a net margin of 0.00% compared to Aytu BioPharma's net margin of -20.43%. Aytu BioPharma's return on equity of 12.38% beat Connect Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Connect BiopharmaN/A N/A N/A Aytu BioPharma -20.43%12.38%3.32% SummaryConnect Biopharma beats Aytu BioPharma on 8 of the 15 factors compared between the two stocks. Get Aytu BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AYTU vs. The Competition Export to ExcelMetricAytu BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.10M$3.11B$5.70B$10.23BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-0.6820.6376.0426.13Price / Sales0.21387.65516.68165.77Price / CashN/A45.9137.5661.52Price / Book0.419.7612.676.32Net Income-$15.84M-$52.73M$3.29B$270.94M7 Day Performance-20.30%0.63%0.09%-0.10%1 Month Performance-17.87%6.30%4.14%6.37%1 Year Performance-22.26%18.52%65.69%28.45% Aytu BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AYTUAytu BioPharma3.7553 of 5 stars$1.89-8.3%$10.25+442.6%-15.2%$17.10M$81.66M-0.68160News CoverageEarnings ReportAnalyst ForecastCNTBConnect Biopharma3.1098 of 5 stars$1.58+0.6%$7.00+343.0%+39.8%$87.48M$26.03M0.00110ASRTAssertio1.8888 of 5 stars$0.93+2.5%$2.38+156.1%-18.5%$87.03M$124.96M-2.0620EQEquillium0.7067 of 5 stars$1.45-0.7%$1.00-31.0%+75.6%$86.88M$41.10M-2.5940News CoverageCNTXContext Therapeutics3.5378 of 5 stars$0.99+2.4%$5.20+424.4%-51.3%$86.85MN/A-2.757OVIDOvid Therapeutics4.2289 of 5 stars$1.29+6.6%$3.10+140.3%+22.8%$86.04M$570K-2.4360Gap UpQNCXQuince Therapeutics3.7932 of 5 stars$1.62+1.3%$8.14+402.6%+114.6%$85.94MN/A-1.4960News CoveragePositive NewsGap UpSLGLSol-Gel Technologies0.1756 of 5 stars$28.01-8.2%N/A+286.5%$84.97M$11.54M-22.7750KLRSKalaris Therapeutics1.3646 of 5 stars$4.40-3.1%$3.00-31.8%N/A$84.91MN/A0.00110ATRAAtara Biotherapeutics4.5832 of 5 stars$12.30+2.1%$21.00+70.7%+88.9%$84.63M$128.94M-28.60330Positive NewsALTSALT5 Sigma0.051 of 5 stars$3.77-3.3%N/A+81.4%$84.28M$12.53M0.00170 Related Companies and Tools Related Companies Connect Biopharma Alternatives Assertio Alternatives Equillium Alternatives Context Therapeutics Alternatives Ovid Therapeutics Alternatives Quince Therapeutics Alternatives Sol-Gel Technologies Alternatives Kalaris Therapeutics Alternatives Atara Biotherapeutics Alternatives ALT5 Sigma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AYTU) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
